TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10748312

Group type: EXPERIMENTAL
Intervention: Patients with chronic heart failure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise time
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heart rate at peak exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Change in heart rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rate pressure product at peak exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Change in systolic blood pressure
Number of subjects: 60
Study: 8761899

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 72
Study: 1431582

Group type: EXPERIMENTAL
Intervention: Oleic acid-rich diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Palmitic acid-rich diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Elaidic acid-rich diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Butter fat diet
Number of subjects: 27
Study: 3857359

Group type: EXPERIMENTAL
Intervention: 0.5 g CTM, given 4 times daily for 5 days (Group A)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 1 g CTM, given twice daily for 5 days (Group B)
Number of subjects: 47
Study: 30157016

Group type: EXPERIMENTAL
Intervention: Engage program (eight clinic‐based sessions supported by online modules)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 27255121

Group type: EXPERIMENTAL
Intervention: Strawberry drink consumed 2 h before the meal (BM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Strawberry drink consumed with the meal (WM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Strawberry drink consumed 2 h after the meal (AM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control drinks at alternative time points
Number of subjects: 14
Study: 24953794

Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rituximab (both dosing arms)
Number of subjects: 12
Study: 22180589

Group type: EXPERIMENTAL
Intervention: SmokeStop Therapy (SST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal Intervention Strategy for Lung patients (LMIS)
Number of subjects: 0
Study: 19904250

Group type: EXPERIMENTAL
Intervention: Double-dosed pantoprazole (40 mg twice daily for 8 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard-dosed pantoprazole (40 mg per day for 8 weeks and one blank tablet at night)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Double-dosed pantoprazole
Number of subjects: 200
Study: 18624724

Group type: EXPERIMENTAL
Intervention: NRTI-sparing regimen
Number of subjects: 100
Study: 15954953

Group type: EXPERIMENTAL
Intervention: Propofol (30 mg boluses every second minute)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitrous oxide (N2O, premedication with 30 mg propofol 5 min before, increased every other minute in 15% increments, max. 75%)
Number of subjects: 20
Study: 15023662

Group type: COMPARATOR
Intervention: No egg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: One cooked egg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: (1/2)cooked egg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: One raw egg
Number of subjects: 41
Study: 10758799

Group type: EXPERIMENTAL
Intervention: General anaesthesia (group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Combined general and epidural anaesthesia (group B)
Number of subjects: 41
Study: 8835706

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 40 to 60 mg daily for 4 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) with lithium carbonate (Li) 2 x 400 mg/day from days 29 to 35
Number of subjects: 69

Group type: COMPARATOR
Intervention: Citalopram (CIT) with placebo (CIT‐Pl)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) with lithium (Li) 800 mg/day from days 36 to 42
Number of subjects: 69
Study: 1451222

Group type: EXPERIMENTAL
Intervention: isoflurane-nitrous oxide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: propofol-air
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: propofol-nitrous oxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 6486112

Group type: EXPERIMENTAL
Intervention: Breakfast containing greater than 30 g fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Breakfast containing less than 15 g fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Breakfast totally free of fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Infusion of C‐terminal octapeptide of cholecystokinin
Number of subjects: 15
Study: 31427339

Group type: EXPERIMENTAL
Intervention: IPCAS model of care including a structured review using a checklist; a self-management programme; enhanced communication pathways between primary care and specialist services; and direct point of contact for patients.
Number of subjects: 920

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: IPCAS model of care
Number of subjects: 920
Study: 29326097

Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer
Number of subjects: 101
Study: 26857421

Group type: EXPERIMENTAL
Intervention: Routine care with additional low dose chest CT
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Routine care including a chest x-ray
Number of subjects: 1724
Study: 25127679

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical tests (FITs), 3 tests (1/year for 3 years), cutoff ≥10 μg hemoglobin/g feces
Number of subjects: 1918

Group type: COMPARATOR
Intervention: Colonoscopy, single examination
Number of subjects: 1918
Study: 22322165

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (fellow-eye)
Number of subjects: 73
Study: 21144937

Group type: EXPERIMENTAL
Intervention: Reamer-Irrigator-Aspirator (RIA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional reamer
Number of subjects: 20
Study: 18061756

Group type: EXPERIMENTAL
Intervention: Relaxation and visualization therapy (RVT) for 24 consecutive days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (radiotherapy only)
Number of subjects: 34
Study: 10665518

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2.0% t.i.d.
Number of subjects: 0
Study: 9487345

Group type: EXPERIMENTAL
Intervention: Diffumal‐24 (once daily at 20.00 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theo‐Dur (twice daily at 08.00 and 20.00 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8149942

Group type: EXPERIMENTAL
Intervention: Buffered aspirin (700 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aspirin with calcium carbonate (700 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aspirin with caffeine (700 mg)
Number of subjects: 7
Study: 3749962

Group type: EXPERIMENTAL
Intervention: Interviewing skills training based on the Developmental Helping Model (10-week course)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditionally focused training (control group)
Number of subjects: 32
Study: 29519353

Group type: EXPERIMENTAL
Intervention: Etidronate (cyclical 20 mg/kg for 2 weeks every 12 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 74
Study: 27801892

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 1714
Number of subjects: 22
Study: 24714816

Group type: EXPERIMENTAL
Intervention: Resistance training (circuit with six stations, 3 days per week for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study: 22112598

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole + Nevirapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotrimoxazole + Placebo
Number of subjects: 0
Study: 20147671

Group type: EXPERIMENTAL
Intervention: Self-rated health (fair or poor)
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Clinical history of myocardial infarction
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Insulin use
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Post-high school education
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Screening Instrument scores, regular exercise, and employment
Number of subjects: 1199
Study: 18249292

Group type: EXPERIMENTAL
Intervention: Eruption guidance appliance
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study: 16181528

Group type: EXPERIMENTAL
Intervention: ZYTF combined with acupuncture and massotherapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Simple Western medicine
Number of subjects: 118
Study: 14616429

Group type: COMPARATOR
Intervention: Melatonin (6 mg) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg) with caffeine (3 x 200 mg)
Number of subjects: 12
Study: 10858839

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 80
Study: 9282610

Group type: EXPERIMENTAL
Intervention: SL Nifedipine 10 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SL Captopril 25 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: IV Metoprolol 15 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SL Nifedipine + IV Metoprolol
Number of subjects: 102
Study: 1658591

Group type: EXPERIMENTAL
Intervention: LAK cells injected i.a on days 10, 14, and 21 after operation with IL-2 injections during 3 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adriamycin treatment only (Control group).
Number of subjects: 30
Study: 31170947

Group type: EXPERIMENTAL
Intervention: MBT-Ai + TAU
Number of subjects: 53

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 53
Study: 28691508

Group type: EXPERIMENTAL
Intervention: Multimodal 15-week intervention programme (INT)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Usual care (C)
Number of subjects: 447
Study: 26446072

Group type: EXPERIMENTAL
Intervention: Abrupt wean with HFNC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Abrupt wean without HFNC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gradual wean with HFNC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gradual wean without HFNC
Number of subjects: 60
Study: 23566246

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or 20 mg/day (group A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (group B) treated according to current recommendations without statin therapy
Number of subjects: 68
Study: 21750010

Group type: EXPERIMENTAL
Intervention: Chignon ankle-foot orthosis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard ankle-foot orthosis
Number of subjects: 28
Study: 19645975

Group type: EXPERIMENTAL
Intervention: Berci-Kaplan Video Laryngoscope (VL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 60
Study: 18830045

Group type: EXPERIMENTAL
Intervention: Vitamin K2 treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytonadione (Vitamin K1) and menaquinone (Vitamin K2)
Number of subjects: 0
Study: 16050219

Group type: EXPERIMENTAL
Intervention: Ultrasound method for imaging the growth plate
Number of subjects: 269

Group type: COMPARATOR
Intervention: X-ray method for imaging the growth plate
Number of subjects: 269
Study: 11826229

Group type: EXPERIMENTAL
Intervention: Xylitol mixture
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control chewing gum
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Xylitol lozenges
Number of subjects: 1277
Study: 10047932

Group type: EXPERIMENTAL
Intervention: Immediate-release carbidopa/levodopa (Sinemet, IR-CL)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Controlled-release carbidopa/levodopa (Sinemet CR, CR-CL)
Number of subjects: 52
Study: 8559497

Group type: EXPERIMENTAL
Intervention: rHuEpo treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no rHuEpo treatment)
Number of subjects: 17
Study: 2044646

Group type: EXPERIMENTAL
Intervention: Sitosterol (3.6 mumol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitostanol (3.6 mumol/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 0
Study: 7140397

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 13
Study: 31746260

Group type: EXPERIMENTAL
Intervention: Starch/gluten-based meals with soybean oil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Starch/gluten-based meals with palm oil
Number of subjects: 8
Study: 30860474

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP5) add-on therapy for 24 weeks with entecavir (ETV) and peginterferon alfa-2a (PegIFN alpha-2a)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Entecavir (ETV) and peginterferon alfa-2a (PegIFN alpha-2a)
Number of subjects: 45
Study: 28745096

Group type: EXPERIMENTAL
Intervention: Tailored Feedback Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study: 26542476

Group type: EXPERIMENTAL
Intervention: Insulation of the ear with ear protectors (Arton 2200)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No insulation of the ear
Number of subjects: 31
Study: 23388507

Group type: EXPERIMENTAL
Intervention: Remifentanil (0-10 ng ml(‐1)) and sevoflurane (0.3-3.4 vol.%)
Number of subjects: 65
Study: 21499755

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 280

Group type: COMPARATOR
Intervention: TVT-Secur
Number of subjects: 280
Study: 19515642

Group type: EXPERIMENTAL
Intervention: DCR with silastic intubation
Number of subjects: 100

Group type: COMPARATOR
Intervention: DCR without silastic intubation
Number of subjects: 100
Study: 17545416

Group type: EXPERIMENTAL
Intervention: Posterior mini‐incision total hip arthroplasty (10 +/- 2 cm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional total hip arthroplasty (long incision, 20 +/- 2 cm)
Number of subjects: 60
Study: 15552353

Group type: EXPERIMENTAL
Intervention: Repetition priming task (perceptual identification)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mere exposure tasks (affective liking or preference judgment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 11903835

Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg four times a day for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9272792

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for moderate pain
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for severe pain
Number of subjects: 1080
Study: 7931432

Group type: EXPERIMENTAL
Intervention: Atraumatic 22-gauge cannula
Number of subjects: 100

Group type: COMPARATOR
Intervention: 20-gauge cannula with a Quincke bevel
Number of subjects: 100
Study: 2906367

Group type: EXPERIMENTAL
Intervention: 10 mg iv dose administered by constant-rate infusion over 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral doses of 10 mg, 20 mg, and 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg iv dose, 10 mg oral dose, 20 mg oral dose, 40 mg oral dose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12
Study: 30376860

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 150
Study: 27243414

Group type: EXPERIMENTAL
Intervention: Postdischarge intervention with a specially trained Community Resource Coordinator
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Postdischarge intervention
Number of subjects: 308
Study: 25535011

Group type: EXPERIMENTAL
Intervention: SSRI medication regimen
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23087419

Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (2.5 mg in 0.1 ml injections)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 30
Study: 19852710

Group type: EXPERIMENTAL
Intervention: Very Early Mobilisation (VEM)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 71
Study: 18212687

Group type: EXPERIMENTAL
Intervention: Combined intra-arterial (IA) plus intramuscular (IM) administration of autologous bone marrow mononuclear cells (BMC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sole intramuscular (IM) administration of autologous bone marrow mononuclear cells (BMC)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined IA+IM administration of autologous BMC
Number of subjects: 27
Study: 15968652

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Biomagnetic Liver Susceptometry (BLS)
Number of subjects: 23
Study: 12454805

Group type: EXPERIMENTAL
Intervention: Nurse-led cognitive-behavioral treatment (CBT) pain management program
Number of subjects: 154
Study: 10322244

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7492164

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoclopramide plus dexamethasone
Number of subjects: 30
Study: 1786051

Group type: EXPERIMENTAL
Intervention: Early mobilisation (Group A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: 24 hour bed rest (Group B)
Number of subjects: 69
Study: 6461916

Group type: EXPERIMENTAL
Intervention: Org 2969 + EE
Number of subjects: 22

Group type: COMPARATOR
Intervention: Levonorgestrel + EE
Number of subjects: 22
Study: 28984096

Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg IV and 0.5 mg/kg/h)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 46
Study: 26175479

Group type: EXPERIMENTAL
Intervention: Intervention designed to reduce substance use, violence and unsafe sex
Number of subjects: 290
Study: 25349864

Group type: EXPERIMENTAL
Intervention: Inhalation technique with spacer
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inhalation technique without spacer
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 23565943

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) intake (150 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (24 mg/kg NaCl)
Number of subjects: 14
Study: 21176203

Group type: EXPERIMENTAL
Intervention: ADHD prison inmates
Number of subjects: 315

Group type: COMPARATOR
Intervention: ADHD psychiatric outpatients
Number of subjects: 315

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 315
Study: 18182623

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training (WBVT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 20
Study: 16403616

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized mite extracts (D.p. and D.f.)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 14606271

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 790
Study: 10925649

Group type: EXPERIMENTAL
Intervention: Polyglyconate screw (femoral bone block fixation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metal screw (tibial fixation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metal screw (both bone blocks)
Number of subjects: 40
Study: 8694295

Group type: EXPERIMENTAL
Intervention: 4.0 mg of intrathecal morphine (Group MS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrathecal saline placebo (Group NS)
Number of subjects: 0
Study: 1286050

Group type: EXPERIMENTAL
Intervention: EEP chemotherapy (Etoposide + Epirubicin + Cisplatin)
Number of subjects: 119

Group type: COMPARATOR
Intervention: FEM chemotherapy (Control)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: EEP chemotherapy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: EEP-FEM comparison
Number of subjects: 119
Study: 3890307

Group type: EXPERIMENTAL
Intervention: CAP combination chemotherapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: CMFVP combination chemotherapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: CAP combination chemotherapy (as second-line treatment)
Number of subjects: 123
Study: 31145885

Group type: EXPERIMENTAL
Intervention: Early insertion of ENG implant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed insertion of ENG implant
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 30307302

Group type: EXPERIMENTAL
Intervention: Dairy products enriched with calcium and vitamin D (250 ml daily)
Number of subjects: 210
Study: 26928895

Group type: EXPERIMENTAL
Intervention: Two-question assent process
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Seven-question assent process
Number of subjects: 568

Group type: COMPARATOR
Intervention: No-question assent process (control)
Number of subjects: 568
Study: 1481657

Group type: EXPERIMENTAL
Intervention: Topical nasal decongestant in different formulations (varied viscosities)
Number of subjects: 0
Study: 22687177

Group type: EXPERIMENTAL
Intervention: Intraoral ultrasound (US)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Landmark technique (LM)
Number of subjects: 28
Study: 20546261

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control subjects (normal OGTT)
Number of subjects: 75